In a market that values both late-stage products and fiscally responsible pharma, spin-outs are a win-win solution, creating a biotech start-up with an experienced team and often products in the clinic while allowing pharma to save on development costs while still potentially receiving money off future products. This panel will explore the various types of spin-outs and what makes a spin-out successful for all parties involved.



Objectives:

Present case studies of spin-outs from biotech/pharma companies, nonprofit organizations and academia.

Discuss spin-out drivers and appropriate stages in the drug/technology development process to spin out.

Present benefits, drawbacks, challenges and tips from both sides of the spin-out process.